## SNPS: Synopsys, Inc. - XLK: Technology

### Executive Summary

No thesis match: MRS_10 1.5% below STRENGTH zone (3.0-6.0%); PEG 2.99 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($450.95)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bearish (Bullish: 0, Bearish: 8)

**1. Synopsys stock today rises as tech slips, Dec. 30 lawsuit deadline nears**
- Source: ts2.tech | 20251229T210026 | Neutral | Relevance: 100%
- Synopsys (SNPS) shares rose 0.4% in afternoon trading, outperforming a generally softer tech market as a Dec. 30 deadline approaches for investors to seek lead plaintiff status in a securities class action lawsuit. The lawsuit alleges misleading statements regarding Synopsys's Design IP business. Investors are also monitoring Fed minutes, jobless claims, and Synopsys's recent restructuring efforts and acquisition of Ansys.

**2. Investors who lost money on Synopsys, Inc.(SNPS) should contact The Gross Law Firm about pending Class Action - SNPS**
- Source: PR Newswire | 20251229T140249 | Bearish | Relevance: 100%
- The Gross Law Firm is notifying shareholders of Synopsys, Inc. (NASDAQ: SNPS) who purchased shares during December 4, 2024, to September 9, 2025, about a pending class action lawsuit. The complaint alleges that Synopsys made materially false and/or misleading statements regarding how its focus on AI customers negatively impacted its Design IP business and financial results. Shareholders are encouraged to contact the firm to potentially be appointed as lead plaintiff before the December 30, 2025 deadline.

**3. Shaky Earnings May Not Tell The Whole Story For Synopsys (NASDAQ:SNPS)**
- Source: Simply Wall Street | 20251229T103205 | Somewhat-Bearish | Relevance: 100%
- Synopsys' recent earnings, despite appearing lackluster, are influenced by significant share dilution and unusual one-off boosting items. The company expanded its shares by 24% over the last year, leading to a 13% decline in EPS even as net profit only dropped by 7.3%. Additionally, unusual items contributed US$597m to the profit, suggesting that the statutory profit may not reflect the underlying financial performance.

**4. Lost Money on Synopsys, Inc. (SNPS)? Join Class Action Before December 30, 2025 - Contact Levi & Korsinsky**
- Source: WJBF | 20251229T080844 | Bearish | Relevance: 100%
- Levi & Korsinsky, LLP has filed a securities class action lawsuit against Synopsys, Inc. (NASDAQ:SNPS) on behalf of investors who suffered losses due to alleged securities fraud between December 4, 2024, and September 9, 2025. The lawsuit claims Synopsys made false statements and concealed information regarding the deteriorating economics of its Design IP business due to increased focus on AI customers. Investors who purchased SNPS securities during this period are encouraged to contact Levi & Korsinsky to explore potential recovery.

**5. Key facts: Synopsys Q3 revenue falls; class action lawsuit filed**
- Source: TradingView â€” Track All Markets | 20251227T200804 | Bearish | Relevance: 100%
- Synopsys (SNPS) reported Q3 revenue of $1.740 billion, falling short of guidance and resulting in a 43% year-over-year decrease in net income. Following this announcement, the company's stock price dropped by 35.84%, and a class action lawsuit has been filed against Synopsys on behalf of investors alleging securities fraud between December 4, 2024, and September 9, 2025.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 6, Lowers: 4)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-12 | Morgan Stanley | $550 | $510 | +8% |
| 2025-12-11 | JP Morgan | $650 | $600 | +8% |
| 2025-12-11 | Wells Fargo | $500 | $445 | +12% |
| 2025-12-11 | Keybanc | $600 | $575 | +4% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-12 | Morgan Stanley | main | Overweight |
| 2025-12-11 | JP Morgan | main | Overweight |
| 2025-12-11 | Wells Fargo | main | Equal-Weight |
| 2025-12-11 | Keybanc | main | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 11 ($0.37M) |
| Sells | 3 ($0.53M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 39.3% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 8 / 2 |

**Top Holders:**
- Vanguard Group Inc: 9.5% (+20.7%)
- Blackrock Inc.: 7.9% (+18.5%)
- State Street Corpora: 4.6% (+20.6%)
- Capital World Invest: 3.9% (-3.7%)
- FMR, LLC: 3.0% (+47.5%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Analyst target momentum: 6 raises (avg +8%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 2.99 signals overvaluation risk, limited margin of safety. Quality metrics strong (margin 19%). Analyst sentiment positive (6 raises, avg +8%). Institutional flow bullish (8 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $91.6B |
| Beta | 1.15 |
| 52W Range | $365.74 - $651.73 |
| Short Interest | 2.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.99 |
| Forward P/E | 28.3 |
| Current P/E | 33.3 |
| YoY Growth | 17.7% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from 2.9% to 1.5% (-1.4% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 1.5pp (needs >3.0% for momentum thesis). MRS_5 at 0.5% confirms short-term momentum alignment. Below SMA200 (0.98x), long-term trend not supportive. MACD histogram positive (1.17), confirming momentum. OFD pattern: +SUL (Resistance test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 1.49% (CS: 92) | Neutral |
| RSI_14 | 63.1 | Neutral |
| MACD Histogram | 1.17 | Bullish |
| vs SMA20 | 1.030x | Above |
| vs SMA50 | 1.093x | Above |
| vs SMA200 | 0.978x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $478.97
- **Stop Loss:** $450.95 (5.9% risk)
- **Target:** $506.99 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 41
- **Position Value:** $19,637.77
- **Portfolio %:** 19.64%
- **Risk Dollars:** $1,150.00
- **Risk Per Trade:** 1.15%
- **Modifiers:** L1 115% | L2 100% | Combined 1.15x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (HIGH) | 1.15x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with selective risk appetite and defensive rotation. VIX at 14.2 (2nd percentile) signals low volatility, while positive yield curve (+58bps) and stable economic indicators support continued expansion. Market breadth at 58.7% shows decent participation, but rotation into defensive names and Fed liquidity concerns warrant measured positioning.*

### Earnings

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q4 | $2.88 | $2.90 | +0.7% |
| 2025Q3 | $3.75 | $3.39 | -9.5% |
| 2025Q2 | $3.40 | $3.67 | +8.0% |
| 2025Q1 | $2.79 | $3.03 | +8.6% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_10*